Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Injection of Filgrastim, of Filgrastim
Filgrastim · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| pegfilgrastim | EXPERIMENTAL | Pegfilgrastim given once after induction chemotherapy |
| filgrastim | ACTIVE_COMPARATOR | Filgrastim given daily after induction chemotherapy |
| Name | Type | Description |
|---|---|---|
| filgrastim | DRUG | Filgrastim given daily after induction chemotherapy |
| pegfilgrastim | DRUG | Pegfilgrastim given once after induction chemotherapy |
| Paclitaxel | DRUG | 1-hour IV infusion once weekly for 12 to 14 weeks |
| Vinorelbine | DRUG | escalating doses administered intravenously over 6-10 minutes for 12-14 weeks |
| Radiation | RADIATION | Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy |
| Epoetin alfa | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion * Histologically confirmed de novo AML as evidenced by absence of an antecedent hematologic disease of \> 1 months duration, prior chemotherapy, prior radiation therapy or myelodysplastic cytogenetics (as per exclusion criteria) * Life expectancy, with treatment, \> 3 months * Age \> 18 y...
Top 20 of 28 competitors